Serum soluble CD27 level is associated with outcome in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone

References

• The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987–994.
   PubMed Web of Science ®Google Scholar
• Coiffer B, Lepage EE Briere JJ. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. 2002;346:235–242.
   Google Scholar
• Fisher RI, Shah P. Current trends in large cell lymphoma. Leukemia 2003;17:1948–1960.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trümper L, Osterborg A, .; MabThera International Trial Group. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379–391.
   Google Scholar
• Goto N. Serum soluble CD27 level is associated with outcome in aggressive non-Hodgkin's Lymphoma. Paper presented at Annual Gifu Hematological Meeting. 9 October 2004. Gifu, Japan.
   Google Scholar
• Swerdlow SH, Campo E Harris NL. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC Press; 2008.
   Google Scholar
• Carbone PP, Kaplan HS, Musshoff K, . Report of the committee on Hodgkin's disease staging classification. Cancer Res 1971;31:1860–1861.
   PubMed Web of Science ®Google Scholar
• Ishii Y, Takami T, Yuasa H, . Two distinct antigen systems in human B lymphocytes: identification of cell surface and intracellular antigens using monoclonal antibodies. Clin Exp Immunol 1984;58: 183–192.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, . Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103: 275–282.
   PubMed Web of Science ®Google Scholar
• Natkunam Y, Warnke RA, Montgomery K, . Analysis of MUM1/IRF4 protein expression using tissue microarrays and immunohistochemistry. Mod Pathol 2001;14:686–694.
   PubMed Web of Science ®Google Scholar
• Sawada M, Tsurumi H, Yamada T, . A prospective study of P-IMVP-16/CBDCA: a novel salvage chemotherapy for patients with aggressive non-Hodgkin's lymphoma who had previously received CHOP therapy as first-line chemotherapy. Eur J Haematol 2002;68: 354–361.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Horning SJ, Coiffer B, . Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244–1253.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Berry B, Chhanabhai M, . The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007;109:1857–1861.
   PubMed Web of Science ®Google Scholar
• Nicolaides C, Dimou S, Pavlidisa N. Prognostic factors in aggressive non-Hodgkin's lymphomas. Oncologist 1998;3:189–197.
   PubMedGoogle Scholar
• Alizadeh AA, Eisen MB, Davis RE, . Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503–511.
   PubMed Web of Science ®Google Scholar
• Wright G, Tan B, Rosenwald A, . A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA 2003;100:9991–9996.
   PubMed Web of Science ®Google Scholar
• Muris J, Meijer C, Vos W, . Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma. J Pathol 2006;208:714–723.
   PubMed Web of Science ®Google Scholar
• Ziepert M, Hasenclever D, Kuhnt E, . Standard international prognostic index remains a valid predictor of outcome for patients with aggressive CD20 + B-cell lymphoma in the rituximab era. J Clin Oncol 2010;28:2373–2380.
   PubMed Web of Science ®Google Scholar
• Saito B, Shiozawa E, Usui T, . Rituximab with chemotherapy improves survival of non-germinal center type untreated diffuse large B-cell lymphoma. Leukemia 2007;21:2563–2566.
   PubMed Web of Science ®Google Scholar
• Winter JN, Weller EA, Horning SJ, . Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP. A prospective correlative study. Blood 2006;107:4207–4213.
   PubMed Web of Science ®Google Scholar
• Costa LJ, Feldman AL, Micallef IN, . Germinal center B (GCB) and non-GCB cell-like diffuse large B cell lymphomas have similar outcomes following autologous haematopoietic stem cell transplantation. Br J Haematol 2008;142:404–412.
   PubMed Web of Science ®Google Scholar
• Fu K, Weisenburger DD, Choi WW, . Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol 2008;26:4587–4594.
   PubMed Web of Science ®Google Scholar
• Ichikawa A, Kinoshita T, Watanabe T, . Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N Engl J Med 1997;337:529–534.
   PubMed Web of Science ®Google Scholar
• Niitsu N, Okabe-Kado J, Kasukabe T, . Prognostic implications of the differentiation inhibitory factor nm23-H1 protein in the plasma of aggressive non-Hodgkin's lymphoma. Blood 1999;94:3541–3550.
   PubMed Web of Science ®Google Scholar
• Niitsu N, Okabe-Kado J, Okamoto M, . Serum nm23-H1 protein as a prognostic factor in aggressive non-Hodgkin lymphoma. Blood 2001;97:1202–1210.
   PubMed Web of Science ®Google Scholar
• Niitsu N, Nakamine H Okamoto M, .; Adult Lymphoma Treatment Study Group, ALTSG. Expression of nm23-H1 is associated with poor prognosis in peripheral T-cell lymphoma. Br J Haematol 2003;123:621–630.
   PubMed Web of Science ®Google Scholar
• Goto H, Tsurumi H, Takemura M, . Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: in combination with the International Prognostic Index. J Cancer Res Clin Oncol 2005;131:73–79.
   PubMed Web of Science ®Google Scholar
• Hara T, Tsurumi H, Takemura M, . Serum-soluble fas level determines clinical symptoms and outcome of patients with aggressive non-Hodgkin's lymphoma. Am J Hematol 2000;64:257–261.
   PubMed Web of Science ®Google Scholar
• Watanuki-Miyauchi R, Kojima Y, Tsurumi H, . Expression of survivin and of antigen detected by a novel monoclonal antibody, T332, is associated with outcome of diffuse large B-cell lymphoma and its subtypes. Pathol Int 2005;55:324–330.
   PubMed Web of Science ®Google Scholar
• Goto N, Tsurumi H, Takemura M, . Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma. Eur J Haematol 2006;77:217–225.
   PubMed Web of Science ®Google Scholar
• Bazan JF. Emerging families of cytokines and receptors. Curr Biol 1993;3:603–606.
   PubMed Web of Science ®Google Scholar
• Hintzen RQ, de Jong R, Lens SM, . CD27: marker and mediator of T-cell activation? Immunol Today 1994;15:307–311.
   PubMedGoogle Scholar
• de Jong R, Brouwer M, Kuiper HM, . Maturation- and differentiation-dependent responsiveness of human CD4 + T helper subsets. J Immunol 1992;149:2795–2802.
   PubMed Web of Science ®Google Scholar
• De Jong R, Brouwer M, Hooibrink B, . The CD27− subset of peripheral blood memory CD4 + lymphocytes contains functionally differentiated T lymphocytes that develop by persistent antigenic stimulation in vivo. Eur J Immunol 1992;22:993–999.
   PubMed Web of Science ®Google Scholar
• Hintzen RQ, de Jong R, Lens SM, . Regulation of CD27 expression on subsets of mature T-lymphocytes. J Immunol 1993; 151:2426–2435.
   PubMed Web of Science ®Google Scholar
• Hintzen RQ, de Jong R, Hack CE, . A soluble form of the human T cell differentiation antigen CD27 is released after triggering of the TCR/CD3 complex. J Immunol 1991;147:29–35.
   PubMed Web of Science ®Google Scholar
• van Oers MH, Pals ST, Evers LM, . Expression and release of CD27 in human B-cell malignancies. Blood 1993;82:3430–3436.
   PubMed Web of Science ®Google Scholar
• Kok M, Bonfrer JM, Korse CM, . Serum soluble CD27, but not thymidine kinase, is an independent prognostic factor for outcome in indolent non-Hodgkin's lymphoma. Tumour Biol 2003;24:53–60.
   PubMed Web of Science ®Google Scholar
• Murase S, Saio M, Takenaka K, . Increased levels of CSF soluble CD27 in patients with primary central nervous system lymphoma. Cancer Lett 1998;132:181–186.
   PubMed Web of Science ®Google Scholar
• Purdue MP, Lan Q, Bagni R, . Prediagnostic serum levels of cytokines and other immune markers and risk of non-Hodgkin lymphoma. Cancer Res 2011;71:4898–4907.
   PubMed Web of Science ®Google Scholar
• Widney D, Gundapp G, Said JW, . Aberrant expression of CD27 and soluble CD27 (sCD27) in HIV infection and in AIDS-associated lymphoma. Clin Immunol 1999;93:114–123.
   PubMed Web of Science ®Google Scholar
• Murase S, Saio M, Andoh H, . Diagnostic utility of CSF soluble CD27 for primary central nervous system lymphoma in immunocompetent patients. Neurol Res 2000;22:434–442.
   PubMed Web of Science ®Google Scholar